Spero Therapeutics (NASDAQ:SPRO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The firm presently has a $12.00 price target on the stock. Zacks Investment Research‘s price objective indicates a potential downside of 1.23% from the company’s current price.

According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “

A number of other research firms have also recently weighed in on SPRO. TheStreet cut shares of Spero Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, July 29th. ValuEngine lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Janney Montgomery Scott started coverage on Spero Therapeutics in a report on Monday. They issued a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of Spero Therapeutics in a report on Wednesday, September 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $21.20.

Shares of NASDAQ:SPRO traded up $0.40 during midday trading on Wednesday, hitting $12.15. The stock had a trading volume of 834 shares, compared to its average volume of 28,252. The company’s 50-day moving average price is $9.93 and its 200-day moving average price is $11.46. The company has a market capitalization of $207.08 million, a P/E ratio of -4.67 and a beta of 2.08. The company has a quick ratio of 13.66, a current ratio of 13.66 and a debt-to-equity ratio of 0.04. Spero Therapeutics has a fifty-two week low of $5.52 and a fifty-two week high of $14.48.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.10). The firm had revenue of $2.16 million for the quarter, compared to analyst estimates of $6.95 million. Spero Therapeutics had a negative return on equity of 33.84% and a negative net margin of 321.37%. Research analysts expect that Spero Therapeutics will post -2.9 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of SPRO. Acadian Asset Management LLC purchased a new stake in shares of Spero Therapeutics during the second quarter valued at about $25,000. Marshall Wace LLP acquired a new stake in Spero Therapeutics during the first quarter worth about $39,000. D.A. Davidson & CO. purchased a new position in shares of Spero Therapeutics during the 2nd quarter valued at approximately $115,000. Wells Fargo & Company MN increased its stake in shares of Spero Therapeutics by 187.9% in the 2nd quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock valued at $157,000 after purchasing an additional 8,915 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Spero Therapeutics by 30.7% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 25,118 shares of the company’s stock worth $290,000 after acquiring an additional 5,895 shares in the last quarter. 50.97% of the stock is owned by hedge funds and other institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Featured Article: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.